December 1-4 marked the annual American Society of Hematology (ASH) Annual Meeting and Exposition. Leading experts convened in San Diego, CA to dive in and address the latest news and research updates in malignant and non-malignant hematology.
CAR-T therapy utilizes resources across the therapeutic spectrum; increased use of this therapy may create challenges in institutional resource capacity, according to new research.
A study sheds light on a “considerable lack” of prognostic marker testing among patients with CLL in the modern era.
The addition of daratumumab to conventional therapy for transplant-ineligible, newly diagnosed multiple myeloma patients reduces the risk of progression or death by 44%.
The PharmaFlow Precision Medicine Test provides similar information, yet is faster than conventional cytogenetics in predicting response to therapy in patients with AML, according to new research.
A survey showed that most patients with CLL want to be involved in therapy decisions and that gender, age, and therapy status influence decision-making.
Triplet regimens incorporating a proteasome inhibitor and an immunomodulatory drug for the treatment of newly diagnosed multiple myeloma were compared for relative effectiveness and tolerability.
A recent study sought to determine whether CAR-T therapy aligned with the recent trend of negligible incremental effectiveness and rising cost per life-year gained of other innovative cancer treatments.
Improvement in supportive care and non-HCT therapies, along with other variables, may contribute to similar benefit of HCT and non-HCT therapies in patients with AML.
A retrospective study assessed whether responses to CAR-T therapy in the real world are comparable to the best responses observed in the ZUMA-1 clinical trial.
Gemtuzumab ozogamicin is safe for patients with AML and APL, but combinations of the drug may be better suited for relapsed or refractory AML with measurable residual disease.